U.S., Jan. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07359482) titled 'sElective Serotonin reuPtake inhibitoRs In posT-covid' on Jan. 14.
Brief Summary: Fatigue, cognitive problems, post-exertional malaise (PEM) and postural orthostatic tachycardia syndrome (POTS) are common and debilitating symptoms after COVID-19. The pathophysiology of post-COVID is not well understood and there is no established biomedical treatment. Treatment options for post-COVID are thus much needed.
A promising candidate intervention is fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), that may reduce post-COVID symptoms because of its regulatory effect on the (neuro) immune system, the hypothalamic-pituitary-adre...